Menu
Select Page

Clinical Pathway Handbook for Hyperbilirubinemia

Fetal Fibronectin Testing

Clinical Pathway Handbook for Hyperbilirubinemia

What is a Clinical Pathway Handbook for Hyperbilirubinemia?

What was originally developed as a Quality-Based Procedure (QBP) for Hyperbilirubinemia has been revised and updated into a best evidence Clinical Pathway for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).

 Objectives

The key objectives of the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (≥ 35 weeks) are to:

  • Ensure all newborns receive bilirubin screening between 24-72 hours of life (if not clinically indicated and performed earlier)
  • Ensure infants receive systematic bilirubin monitoring as per the treatment graph and risk nomograms recommended by evidence-based guideline
  • Utilize health care resources responsibly through avoidance of unnecessary/excessive testing, timely discharge, appropriate outpatient follow-up and minimization of preventable readmission
  • Reduce the incidence of severe hyperbilirubinemia and acute bilirubin encephalopathy

Resources

Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks)

A revised and updated version of the QBP for Hyperbilirubinemia.

Summary of Changes

A brief update of the changes made to the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).

Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks) Clinical Pathway Toolkit

An abridged version of the Clinical Pathway Handbook focusing on the clinical pathway.

QBP for Hyperbilirubinemia – Webinar Slides

Previously offered February 21st, 2014 and March 4th, 2014.

QBP for Hyperbilirubinemia – Webinar Q & A

This document was developed based on questions from the February 21st, 2014 and March 4th 2014 webinar sessions.